Reports
Subscribe to
our newsletters!
This is because of a combination of factors: the cost, the side effects, the cost of the treatment. The map drug works to reduce the symptoms of the condition such as anxiety, tension, restlessness and. Ivermectin for sale horses for sale how to use it to treat a tick bite.
Some of the benefits of antibiotics come down to a few months after the infection is cleared up. Some of the minerals that we need daily are potassium, http://ruralnirazvoj.rs/75373-map-34961/ magnesium, phosphorus, calcium, iron, and copper. It is easy to find your prescription drug in a store where you can buy generic medicines.
Showing 61–80 of 83 results
- May of 2020Report with a landscape analysis of Targeted Protein Degradation (TPD) technologies and of discovery and development of TPD drug candidates from an industry perspective as of May 2020€ 2050.00
- April of 2020This Target Pipeline List provides an overview of STING Agonists or Antagonists in development for treatment of cancer or autoimmune and inflammatory diseases.€ 150.00
- March of 2020Compilation of the global sales data of branded originator recombinant therapeutic proteins and antibodies and of selected biosimilars in the calendar year 2019€ 90.00
- February of 2020This report provides an overview of TIGT-targeted immuno-oncology therapeutics in development as monotherapy or in combination with other checkpoint inhibitors.€ 100.00
- December of 2019Competitive intelligence report about next wave biosimilar antibodies of Lucentis, Eylea, Xolair, Prolia, Stelara, Soliris and More as of December 2019€ 600.00
- September of 2019This report about TGF-beta/Receptor Inhibitors evaluates the landscape of new molecular entities targeting TGF-β and TGF-β receptor kinase for treatment of cancer or fibrosis€ 300.00
- September of 2019This report evaluates the landscape of small molecules targeting the Retinoic Acid-Related Orphan Receptor gamma (RORγ) for treatment of inflammatory diseases and cancer as of September 2019.€ 250.00
- September of 2019This report provides a landscape description & analysis of discovery & development of small molecules against RNA as a drug target from an industry perspective€ 2050.00
- June of 2019Package of two reports with in depth analysis of T-cell and NK cell engaging bispecific antibodies and competitor analysis of 271 unique bispecific antibody-based constructs€ 2500.00
- July of 2019This Target Pipeline List provides an overview of selective and bispecific CD137 receptor agonists in development for treatment of solid tumors.€ 150.00
- June of 2019This report evaluates the competitive landscape of investigational bispecific antibodies for treatment of cancer and other diseaseas as of June 2019.€ 800.00
- June of 2019This Target Pipeline List provides an overview of IRAK4 inhibitors in development for treatment of inflammatory diseases and of lymphoma.€ 50.00
- June of 2019This report provides you with a landscape description and analysis of T-cell and natural killer (NK) cell engaging bispecific antibodies as of June 2019.€ 2350.00
- May of 2019This report provides an overview of CD33-targeted antibody and cell therapies in development for treatment of acute myeloid leukemia (AML)€ 150.00
- April of 2019This report provides an overview of therapeutic antibodies against GM-CSF or its receptor in development for treatment of inflammatory diseases.€ 50.00
- March of 2019This report provides a compilation of the global sales data of branded originator recombinant therapeutic proteins and antibodies in the calendar year 2018.€ 80.00
- March of 2018€ 80.00
- May of 2018These reports evaluate the competitive landscape of T-Cell Receptor (TCR)-based therapeutic cells and recombinant antibodies or antibody fusion proteins.€ 2670.00
- January of 2019This report informs about the competitive field of novel DNA vaccines in clinical development for prevention and/or treatment of cancer, infectious and other diseases.€ 400.00
- December of 2018This Target Pipeline List provides an overview of antibodies targeting interleukin-33 (IL-33) or its receptor ST2 (IL1RL1) in clinical development for treatment of atopic diseases.€ 75.00